-

FineHeart Receives Slovenia JAZMP (Agency for Medicinal Products and Medical Devices of the Republic of Slovenia) Authorization to Launch Its FIH Clinical Study on Patients Suffering From Advanced Heart Failure

BORDEAUX, France & LJUBLJANA, Slovenia--(BUSINESS WIRE)--FineHeart S.A., a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announces that it has received authorization from JAZMP, the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia, to begin its First-In-Human (FIH) clinical study.

This prospective, non-randomized study is designed to assess the safety, implant feasibility and preliminary clinical performance of the FlowMaker® device in patients with advanced heart failure.

FlowMaker® is a new-generation, fully implantable left ventricular assist device designed to work in synergy with the heart's natural contraction. Less invasive than current devices, this technology aims to preserve native cardiac function while significantly improving patients' quality of life.

Professor Ivan Kneževič, MD.PhD, cardio surgeon and director of the Transplantation Centre of the University Medical Centre in Ljubljana, will lead the study. "It is a real privilege to take part in this first FIH study. FlowMaker represents a major technological advance in the treatment of patients with advanced heart failure" he said.

Arnaud Mascarell, CEO and co-founder of FineHeart, comments: "Following approvals in the Czech Republic and France, the Slovenian authorization represents another strong endorsement of our preliminary clinical results and our technology by European health authorities. It reflects the growing confidence within the cardiology community in our disruptive approach. This latest green light reinforces our clinical strategy across Europe—a critical step toward securing CE marking. Our goal remains clear: to deliver an innovative, less invasive solution for patients with advanced heart failure, where current treatment options remain limited."

About FineHeart - FineHeart

Contacts

Europe
Media Relations
Annie-Florence Loyer
afloyer@newcap.fr
+33 (6) 88 20 35 59

FineHeart Communications
James Palmer
j.palmer@orpheonfinance.com
+33 (0) 7 60 92 77 72

FineHeart S.A.


Release Versions

Contacts

Europe
Media Relations
Annie-Florence Loyer
afloyer@newcap.fr
+33 (6) 88 20 35 59

FineHeart Communications
James Palmer
j.palmer@orpheonfinance.com
+33 (0) 7 60 92 77 72

More News From FineHeart S.A.

FineHeart Named Leader of the IPCEI Health Tech4Cure to Spearhead the Structuring of the European Implantable Medical Device Sector

BORDEAUX, France--(BUSINESS WIRE)--FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, has been designated as the lead partner of the IPCEI Tech4Cure (Important Project of Common European Interest), dedicated to the implantable medical device (IMD) sector. This project is jointly notified by six EU Member States – France, Hungary, Italy, Latvia, Slovakia, and Slovenia FineHeart will carry out its SmartDMIA program to str...

FineHeart Receives ANSM1 Authorization to Deploy Its First-In-Human Clinical Study in France

BORDEAUX, France--(BUSINESS WIRE)--FineHeart S.A., a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announces that it has received authorization from the French National Agency for the Safety of Medicines and Health Products (ANSM) to initiate its First-In-Human (FIH) clinical trial in France. This prospective, non-randomized study is designed to assess the safety, implant feasibility and preliminary clinical performance of the...

FineHeart announces the appointment of Sébastien Robitaille as Chief Financial Officer

BORDEAUX, France--(BUSINESS WIRE)--FineHeart S.A., a clinical-stage medtech company developing breakthrough solutions for cardiology, announces the appointment of Sébastien Robitaille as Chief Financial Officer. Driven by the challenges of scaling up innovative healthcare companies, Sébastien brings over 25 years of professional experience, primarily in the pharmaceutical and biotechnology industries, with solid expertise in business transformation and financing, including on the Nasdaq. Sébast...
Back to Newsroom